Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Burosumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 10Crysvita

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Crysvita

    Burosumab-twza

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Crysvita

    U.S.A
    arrow
    BioFlorida Conference
    Not Confirmed

    Ultragenyx Pharm Inc

    Burosumab-twza

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2019 Revenue in Millions : 4

    2018 Revenue in Millions : 1

    Growth (%) : 566

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Crysvita

    burosumab-twza

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Crysvita

    Japan
    arrow
    BioFlorida Conference
    Not Confirmed

    Kyowa Kirin

    burosumab-twza

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2020 Revenue in Millions : 550

    2019 Revenue in Millions : 309

    Growth (%) : 78

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Crysvita

    Burosumab-twza

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Crysvita

    U.S.A
    arrow
    BioFlorida Conference
    Not Confirmed

    Ultragenyx Pharm Inc

    Burosumab-twza

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2020 Revenue in Millions : 10

    2019 Revenue in Millions : 4

    Growth (%) : 141

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Crysvita

    burosumab-twza

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Crysvita

    Japan
    arrow
    BioFlorida Conference
    Not Confirmed

    Kyowa Kirin

    burosumab-twza

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2021 Revenue in Millions : 722

    2020 Revenue in Millions : 550

    Growth (%) : 47

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Crysvita

    Burosumab-twza

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Crysvita

    U.S.A
    arrow
    BioFlorida Conference
    Not Confirmed

    Ultragenyx Pharm Inc

    Burosumab-twza

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2021 Revenue in Millions : 21

    2020 Revenue in Millions : 10

    Growth (%) : 107

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Crysvita

    burosumab-twza

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Crysvita

    Japan
    arrow
    BioFlorida Conference
    Not Confirmed

    Kyowa Kirin

    burosumab-twza

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2022 Revenue in Millions : 961

    2021 Revenue in Millions : 722

    Growth (%) : 33

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Crysvita

    Burosumab-twza

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Crysvita

    U.S.A
    arrow
    BioFlorida Conference
    Not Confirmed

    Ultragenyx Pharm Inc

    Burosumab-twza

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2022 Revenue in Millions : 43

    2021 Revenue in Millions : 21

    Growth (%) : 99

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Crysvita

    Burosumab-twza

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Crysvita

    Japan
    arrow
    BioFlorida Conference
    Not Confirmed

    Kyowa Kirin

    Burosumab-twza

    Main Therapeutic Indication : Genetic Diseases

    Currency : USD

    2023 Revenue in Millions : 1,028

    2022 Revenue in Millions : 961

    Growth (%) : 20

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Crysvita

    Burosumab-twza

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Crysvita

    U.S.A
    arrow
    BioFlorida Conference
    Not Confirmed

    Ultragenyx Pharm Inc

    Burosumab-twza

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2023 Revenue in Millions : 76

    2022 Revenue in Millions : 43

    Growth (%) : 77

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Crysvita

    burosumab-twza

    arrow
    BioFlorida Conference
    Not Confirmed

    Brand Name : Crysvita

    Japan
    arrow
    BioFlorida Conference
    Not Confirmed

    Kyowa Kirin

    burosumab-twza

    Main Therapeutic Indication : Genetic Disorders

    Currency : USD

    2019 Revenue in Millions : 303

    2018 Revenue in Millions : 72

    Growth (%) : 323

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF